found that the combination of natural killer cell activity and methylation status of HOXA9 ctDNA in NSCLC patients receiving programmed cell death protein 1 (PD‐1)/its ligand PD‐L1 inhibitor therapy has prognostic value. Here, PDCD1 is linked to non-small cell lung carcinoma.